afnm.com
域名年龄: 22年6个月29天HTTP/1.1 200 OK 访问时间:2019年09月20日 15:58:04 X-Adblock-Key: MFwwDQYJKoZIhvcNAQEBBQADSwAwSAJBAKX74ixpzVyXbJprcLfbH4psP4+L2entqri0lzh6pkAaXLPIcclv6DQBeJJjGFWrBIF6QMyFwXT5CCRyjS2penECAwEAAQ==_WmFAU6hdeZ+zwn7Q2n2Kna4LU4phyCIBt8ncz1YyEq1ML66DvlZC0TCHIUfWoz5sarGII1toOiAyHBzYu5dq/g== 文件大小:1771 Keep-Alive: timeout=5, max=26 连接:Keep-Alive 类型:text/html; charset=UTF-8 网站编码:UTF-8
Skip to content Main Navigation: About Affinium Corporate Information Management Board of Directors Scientific Advisors Programs AFN–1252 FabI Inhibitor Program Publications News News Archives Contact Us TARGETED ANTIBIOTICS FOR SERIOUS INFECTIONS Affinium is a specialty pharmaceutical company developing a novel class of antibiotics that target the bacterial fatty acid synthesis pathway. AFN-1252, our lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains. SEPTEMBER 5, 2013 Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round Click for PDF version (PDF 35KB) MARCH 20, 2013 Affinium Pharmaceuticals Announces Positive Efficacy, Safety, and Tolerability Results from Phase 2a Clinical Trial of Oral AFN-1252 in Acute Bacterial Skin & Skin Structure Infections Click for PDF version (PDF 245KB) MARCH 13, 2013 Affinium Pharmaceuticals, Ltd., Announces the Appointments of Ed Mascioli, MD to the Position of Chief Executive Officer and Robert Radie to the Board of Directors Click for PDF version (PDF 48KB) AUGUST 7, 2012 Affinium Pharmaceuticals, Ltd., A nnounces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections Click for PDF version (PDF 28KB) Tab1 Tab2 Tab3 Tab4 More Kaplan, Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor Parsons, Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors More You can meet us at: ICAAC 2013, September 10-13, 2013. Denver, CO IDWeek 2013, October 2-6, 2013. San Francisco, CA Copyright © 2011 Affinium Pharmaceuticals Footer Navigation: Site Map Contact Us
© 2010 - 2020 网站综合信息查询 同IP网站查询 相关类似网站查询 网站备案查询网站地图 最新查询 最近更新 优秀网站 热门网站 全部网站 同IP查询 备案查询
2024-05-16 22:10, Process in 0.0112 second.